- Report
- August 2024
- 100 Pages
Global
From €5222EUR$5,950USD£4,518GBP
- Report
- May 2025
- 192 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- April 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- July 2025
- 367 Pages
Global
From €5134EUR$5,850USD£4,442GBP
- Report
- January 2025
- 130 Pages
Global
From €2632EUR$2,999USD£2,277GBP
- Report
- June 2025
- 400 Pages
Global
From €4343EUR$4,949USD£3,758GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1316EUR$1,500USD£1,139GBP
- Report
- March 2025
- 180 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- June 2025
- 122 Pages
Global
From €1922EUR$2,190USD£1,663GBP
- Report
- August 2024
- 85 Pages
United States
From €2611EUR$2,975USD£2,259GBP
€3072EUR$3,500USD£2,658GBP
- Report
- February 2025
- 110 Pages
Global
From €4256EUR$4,850USD£3,683GBP
- Report
- June 2023
- 115 Pages
Global
From €3949EUR$4,500USD£3,417GBP
- Report
- March 2024
- 200 Pages
Global
From €3642EUR$4,150USD£3,151GBP
- Report
- August 2023
- 217 Pages
Global
From €6582EUR$7,500USD£5,695GBP
- Report
- August 2022
- 30 Pages
Global
From €2852EUR$3,250USD£2,468GBP
- Report
- August 2022
- 30 Pages
Global
From €2413EUR$2,750USD£2,088GBP
- Report
- August 2022
- 30 Pages
Global
From €2413EUR$2,750USD£2,088GBP
- Report
- January 2022
- 60 Pages
Global
From €3467EUR$3,950USD£2,999GBP
- Report
- January 2024
- 149 Pages
Global
From €2194EUR$2,500USD£1,898GBP
- Report
- February 2024
- 106 Pages
Global
From €4169EUR$4,750USD£3,607GBP

Fabry Disease is a rare, inherited disorder caused by the deficiency of an enzyme called alpha-galactosidase A. This deficiency leads to the accumulation of a fatty substance called globotriaosylceramide (GL-3) in the body's cells, resulting in a wide range of symptoms. Endocrine and Metabolic Disorders Drugs are used to treat Fabry Disease, including enzyme replacement therapy (ERT) and chaperone therapy. ERT is the most common treatment, and involves the administration of a recombinant form of the missing enzyme. Chaperone therapy is a newer treatment option, and involves the use of small molecules to help the body's cells process GL-3.
The Fabry Disease Drug market is a rapidly growing segment of the Endocrine and Metabolic Disorders Drugs market. Companies in the market include Sanofi, Amicus Therapeutics, Shire, and Pfizer. Show Less Read more